Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
where to buy fat dildos? - LovToyLand.com
Popular Articles

ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data In Crohn's Disease To Be Featured In Oral Presentation At 2009 Digestive Disease Week
ChemoCentryx, Inc., announced that data from the company"s PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn"s disease Trial) Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn"s disease will be presented in an oral session at the upcoming 2009 Digestive Disease Week (DDW) meeting. Traficet-EN is an orally-available small molecule drug that controls the inappropriate immune system response underlying inflammatory bowel diseases by blocking the CCR9 chemokine receptor. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn"s disease and other inflammatory disorders of the gastrointestinal system. DDW 2009 will be held on May 30 - June 4, 2009, at McCormick Place in Chicago, Illinois.
diet pills
The Science Of Sedentary Behavior: Too Much Sitting And Too Little Exercise
Sedentary behavior is becoming an important component of the exercise and health equation. There is new evidence that prolonged, unbroken sitting time is related to people"s risk of obesity and type 2 diabetes, according to a lecture presented today at the 56th Annual Meeting of the American College of Sports Medicine (ACSM) in Seattle. Examples of sedentary behaviors include watching television, playing video games, using the computer, reading, and doing homework.
News of the day
To Promote Cardiovascular Health, Tulane University Partners With South American Universities
Cardiovascular disease researchers at Tulane University are partnering with faculty at the University of Buenos Aires, Argentina, to establish the South American Center of Excellence in Cardiovascular Health. The center has received a five-year, $2.3 million dollar grant from the National Heart, Lung and Blood Institute of the National Institutes of Health.
Cardiovascular

Total Artificial Heart Bridges People Rejecting Donor Hearts To 2nd Transplant

During 2008, 10% of people who were implanted with the SynCardia temporary CardioWest™ Total Artificial Heart received the device because they were suffering from rejection of their donor heart transplant. Jim Hennigan, 44, received his first heart transplant in 2004 but suffered from rejection of the new heart. In July 2008, doctors implanted Hennigan with the Total Artificial Heart and bridged him to a second heart transplant 310 days later. "The Total Artificial Heart did a phenomenal job of keeping me healthy and active for more than 10 months," said Hennigan, who was transplanted on May 8, 2009. "As a matter of fact, the Total Artificial Heart was so efficient that my body is still trying to adapt to my new "run of the mill" human heart." Implantation of the Total Artificial Heart is similar to a heart transplant in that it replaces both heart ventricles, eliminating biventricular heart failure. However, unlike a donor heart, the Total Artificial Heart has no risk of rejection because it is made of biocompatible materials. "For someone suffering from donor heart rejection, surgical implantation of any other device will increase the risk of infection because the patient is still taking immunosuppressant drugs for their donor heart," said Richard Smith, MSEE, CCE, Director of the Artificial Heart Program at University Medical Center and Chief Technical Officer for SynCardia. "The Total Artificial Heart is the only device that replaces the donor heart and eliminates the need for immunosuppressant drugs." SynCardia Total Artificial Heart


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009